AD-CDO: A Lightweight Ontology for Representing Eligibility Criteria in Alzheimer's Disease Clinical Trials

TL;DR

This paper presents AD-CDO, a lightweight, semantically enriched ontology that standardizes key eligibility criteria concepts in Alzheimer's disease clinical trials, facilitating trial modeling and data integration.

Contribution

The study introduces AD-CDO, a novel, optimized ontology for AD trial eligibility criteria, with high coverage and practical applications in trial simulation and entity normalization.

Findings

Achieved over 63% coverage of trial concepts.

Demonstrated utility in trial simulation and entity normalization.

Supported downstream applications like phenotyping and cohort identification.

Abstract

Objective This study introduces the Alzheimer's Disease Common Data Element Ontology for Clinical Trials (AD-CDO), a lightweight, semantically enriched ontology designed to represent and standardize key eligibility criteria concepts in Alzheimer's disease (AD) clinical trials. Materials and Methods We extracted high-frequency concepts from more than 1,500 AD clinical trials on ClinicalTrials.gov and organized them into seven semantic categories: Disease, Medication, Diagnostic Test, Procedure, Social Determinants of Health, Rating Criteria, and Fertility. Each concept was annotated with standard biomedical vocabularies, including the UMLS, OMOP Standardized Vocabularies, DrugBank, NDC, and NLM VSAC value sets. To balance coverage and manageability, we applied the Jenks Natural Breaks method to identify an optimal set of representative concepts. Results The optimized AD-CDO achieved over 63% coverage of extracted trial concepts while maintaining interpretability and compactness. The ontology effectively captured the most frequent and clinically meaningful entities used in AD eligibility criteria. We demonstrated AD-CDO's practical utility through two use cases: (a) an ontology-driven trial simulation system for formal modeling and virtual execution of clinical trials, and (b) an entity normalization task mapping raw clinical text to ontology-aligned terms, enabling consistency and integration with EHR data. Discussion AD-CDO bridges the gap between broad biomedical ontologies and task-specific trial modeling needs. It supports multiple downstream applications, including phenotyping algorithm development, cohort identification, and structured data integration. Conclusion By harmonizing essential eligibility entities and aligning them with standardized vocabularies, AD-CDO provides a versatile foundation for ontology-driven AD clinical trial research.